Comparing survival outcomes for cervical cancer based on the 2014 and 2018 International Federation of Gynecology and Obstetrics staging systems

Wonkyo Shin1, Tae Young Ham2, Young Ran Park2, Myong Cheol Lim1,3,4,5 & Young‑Joo Won2,5*

The International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging system was modified in 2018, introducing new stage IB subdivisions and new lymph node status considerations in stage IIIC. We compared cervical cancer survival outcomes according to the 2014 and 2018 FIGO staging systems. We selected 10% of cervical cancer cases (2010–2015) from the Korean national cancer registry (2010–2015) through a systematic sampling method. We collected information using a collaborative stage data collection system and evaluated the results according to both staging systems. The log-rank test was used to analyze overall survival differences. No significant difference in survival was observed between 2018 subdivisions IB1/IB2/IB3 (P = 0.069), whereas a considerable difference was observed between these subdivisions according to histological subtypes. In the 2018 FIGO staging system, stage IIIC had better survival than stage IIIA/IIB (P < 0.001). We observed considerable heterogeneity in 2018 stage IIIC related to the corresponding stages of the 2014 staging system (stages IA1–IIIB). The size of the primary cervical mass was related to survival (P < 0.001). In conclusion, using lymph node status to define stage IIIC captured a broad range of prognoses. The inclusion of primary tumor size considerations may improve the staging accuracy of advanced cervical cancer.

Clinical staging is a standard approach for classifying patients with cervical cancer1, and the extent of local cervical mass spreading is considered one of the most important prognostic factors, relative to lymphatic or hematogenous metastasis. Thus, lymph node status was not included in the staging of cervical cancer, unlike for other gynecologic malignancies, such as ovarian or endometrial cancers2,3. After clinical staging, imaging may be used to determine the type of surgery and the need for adjuvant treatment, or it may be used to guide non-surgical treatment using radiotherapy or concurrent chemoradiotherapy. The extent of the primary cervical mass can also vary according to the type of clinical examination, imaging modality, and pathological findings, although this does not lead to re-staging of the tumor. The categorizations in the 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system were changed to reflect the different imaging modalities that are used after clinical examination, which vary according to institution and region. The goal of this modification was to reduce morbidity by accurately staging the disease and guiding appropriate treatment, which can reduce the need for re-operation and radiation therapy4–7.

Lymph node status remains a controversial factor in the staging of cervical cancer, although lymph node metastasis is associated with a poor prognosis among patients with the same stage of cervical cancer8–10. In addition, a tumor diameter cut-off of 4 cm is used to divide stage IB1/IB2 and stage IIA1/IIA2 in 2014 FIGO system, and there is also a need to consider further subdividing tumors with a diameter of < 4 cm11,12. The 2014 FIGO stage IB1 classification was subsequently divided into IB1 and IB2 in the 2018 FIGO system, while the 2014

1Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea. 2Division of Cancer Registration and Surveillance, National Cancer Center, 323 Ilsan-ro, Ilsan-dong-gu, Goyang 10408, Korea. 3Center for Clinical Trials, National Cancer Center, Goyang, Korea. 4Division of Tumor Immunology, National Cancer Center, Goyang, Korea. 5Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea. *email: astra67@ncc.re.kr
stage IB2 was re-defined as stage IB3 in the 2018 system. Furthermore, the 2018 FIGO system considered lymph node status for stage IIIC disease, with pelvic lymph node metastasis categorized as stage IIIC1 and para-aortic lymph node metastasis categorized as stage IIIC2 (regardless of primary tumor size), based on pathological or radiological results (Supplementary Table 1).

Matsuo et al. performed a validation study of the 2018 FIGO staging system using the Surveillance, Epidemiology, and End Results data. Interestingly, a significant difference was observed between the stage IB1/IB2 subdivisions, with a somewhat meaningful difference in the histological characteristics of the stage IB1/IB2/IB3 classifications (e.g., adenocarcinoma was more common in stage IB1 and squamous cell carcinoma was most common in stage IB3). Furthermore, the survival curves for stage IIC1 were superior to those for stage IIIA/IIIB, which was attributed to the heterogeneity of stage IIC1 cases. However, the Surveillance, Epidemiology, and End Results data did not include para-aortic lymph node status, which precluded an analysis of stage IIIC2, and there were limited data regarding the radiological or pathological findings for lymph node status. Therefore, the present study aimed to compare survival outcomes between the 2014 and 2018 FIGO systems, to determine the utility of the new 2018 FIGO staging system, using data from the Korean national cancer registry.

**Results**
A total of 2441 patients with cervical cancer were included in this study and their baseline characteristics are shown in Table 1. Figure 1 shows the survival curves for 2018 FIGO stage IB subgroups (except for stage unknown). A small but non-significant difference was observed between the survival curves for 2018 FIGO stage IB1/IB2/IB3 subdivisions (P = 0.069). We also evaluated the histological classifications for stage IB subgroups, which revealed that squamous cell carcinoma was more common in stage IB3 than that in stage IB1 (74.6% vs. 70.3%), whereas adenocarcinoma was more common in stage IB1 than that in stage IB3 (25.4% vs. 18.5%). Intermediate results were observed for stage IB2. Adenosquamous carcinoma accounted for the smallest proportion of cases in the subgroups (Table 2).

We also analyzed data for the newly added 2018 FIGO stage IIIC, with pelvic lymph node metastasis classified as stage IIIC1 and para-aortic lymph node metastasis classified as stage IIIC2, based on either radiological or pathological confirmation. It is important to note that patients with stage IIIC from the 2018 FIGO system would have been assigned to other groups based on the 2014 FIGO system. In the 2018 FIGO system, stage IIC1/IIIC2 had better survival than stage IIIA/IIIB, and stage IIC1 had better survival than stage IIIC2 (P < 0.001) (Fig. 2). Patients in the stage IIIC group from the 2018 FIGO system were most commonly assigned to stage IIB in the 2014 FIGO system, although the 2014 stages ranged broadly from IA1 to IIIB (Fig. 3). We also sub-classified the stage IIIC group according to the T classification of the primary cervical mass and observed significant differences in the survival curves for T1, T2, and T3 (P < 0.001) (Supplementary Figure S1).

**Discussion**
Previous reports have suggested that the 2014 FIGO stage IB1 group should be further subdivided. Furthermore, in 2018, the results of the LAAC trial (locally advanced cervical cancer) reported that laparoscopic surgery is more dangerous than laparotomy for locally advanced cervical cancer. However, many reports have suggested that laparoscopic surgery was not dangerous if the cervical mass was small. Thus, the division of stage IB1 from the 2014 FIGO system into stage IB1/IB2 from the 2018 FIGO system may help better guide patient management. In addition, the 2018 European Society of Gynecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines suggested that immediate concurrent chemoradiotherapy might be considered without surgery if the cervical mass was > 2 cm, rather than > 4 cm. Thus, the new 2018 staging system may be useful. Although the present study failed to detect a significant difference in survival between the new stages IB1 and IB2 (P = 0.069), a significant difference was detected in the analysis of Surveillance, Epidemiology, and End Results data from the US (P < 0.001). This discrepancy may be related to the difference in the sample sizes of stage IB cases between the two studies (approximately 8000 patients from the Surveillance, Epidemiology, and End Results database versus only approximately 1000 patients in the present study).

Furthermore, according to the FIGO 2018 staging system, if the LN metastasis is radiologically or pathologically confirmed, it is categorized as stage IIIC, not stage I. Notably, heterogeneity in stage I did not occur due to other prognostic factors, since it was analyzed only with the size of the original cervix mass.

The radicality of hysterectomy is also generally different for cases involving stage IB1 or IB2 disease. However, the Surveillance, Epidemiology, and End Results data analysis only considered simple or extended hysterectomy, while the present study was unable to determine the extent of surgery, which may have affected our findings. There are several criteria to consider when identifying hysterectomy types in patients with cervical cancer, and the most widely used are those associated with the Querleu–Morrow classification. The surgical factors are very important in determining the subsequent prognosis, which suggests that a detailed analysis of surgical factors is needed to confirm the survival difference between stage IB1 and IB2 cases.

The incidence of AC is relatively high in IB1, and the incidence of SCC is high in IB3. In this aspect, it is necessary to consider that SCC and AC have different pathophysiology, which includes epidemiology, tumor spreading pattern, and prognosis. SCC typically spreads locally and invades adjacent organs, whereas AC more frequently exhibits a lymphatic or hematogenous tumor cell spreading pattern. Therefore, as the size of the primary site increases, the probability of AC spreading to other organs increases. Consequently, it is possible for a patient to be diagnosed as a stage III or higher, but not IB3.

The new stage IIIC criteria consider lymph node status based on clinical, radiological, and pathological findings. Interestingly, the present study revealed that stage IIC1/IIIC2 had better survival than stage IIIA/IIIB. Further analysis of the stage IIIC group from the 2018 FIGO system revealed broad differences in staging...
According to the 2014 FIGO system (ranging from stages IA1 to IIIB) (Fig. 3). Traditionally, the FIGO staging of cervical cancer has been determined by the size and adjacent invasion extent of the primary cervical mass. The 2018 system only considers lymph node status for stage IIIC and omits the cervical tumor’s extent and invasion status. This definition of stage IIIC may lead to better survival outcomes for stage IIIC, relative to stage IIIA/IIIB.

We evaluated this issue by considering survival in stage IIIC cases according to T classification (Supplementary Figure S1), which revealed significant survival differences according to T classification. Therefore, it appears that only considering lymph node status is insufficient for determining the clinical characteristics of stage IIIC cervical cancer and may not be appropriate in a clinical setting, given the heterogeneity in this patient group. Lymph node metastasis is classified as an isolated tumor cells (if LN size < 0.2 mm), micrometastasis (0.2 mm < LN < 2 mm), and macrometastasis (> 2 mm). For isolated tumor cells, it is recorded in the pathologic report, but it is not classified as stage IIIC. Micrometastasis is also regarded as macrometastasis. Although, our data do not have the detailed LN status; comparing the survival according to the LN metastatic status could show interesting results.

By adding lymph node status, the difference between 2018 FIGO staging and TNM staging has been reduced, although the 2018 FIGO system still creates a heterogeneous stage IIIC group. Thus, additional information regarding the primary cervical mass is needed to reduce the heterogeneity in stage IIIC. The standard treatments for locally advanced cervical cancer can involve radical hysterectomy, radiotherapy, or concurrent treatments for locally advanced cervical cancer can involve radical hysterectomy, radiotherapy, or concurrent

### Table 1. Baseline characteristics of Korean patients with cervical cancer. FIGO International Federation of Gynecology and Obstetrics, AJCC American Joint Committee on Cancer.

| Category                  | All patients N=2441 n (%) |
|---------------------------|---------------------------|
| Age (years)               |                           |
| < 40                      | 438 (17.9)                |
| 40–49                     | 632 (25.9)                |
| 50–59                     | 570 (23.4)                |
| 60–69                     | 353 (14.5)                |
| ≥ 70                      | 448 (18.4)                |
| Year at diagnosis         |                           |
| 2010                      | 443 (18.2)                |
| 2011                      | 407 (16.7)                |
| 2012                      | 404 (16.6)                |
| 2013                      | 407 (16.7)                |
| 2014                      | 396 (16.2)                |
| 2015                      | 384 (15.7)                |
| Histological subtype      |                           |
| Squamous cell carcinoma   | 1897 (77.7)               |
| Adenocarcinoma            | 379 (15.5)                |
| Adenosquamous carcinoma   | 62 (2.5)                  |
| Others                    | 103 (4.2)                 |
| AJCC 7th edition, T status|                           |
| T1                        | 1415 (58.0)               |
| T2                        | 663 (27.2)                |
| T3                        | 174 (7.1)                 |
| T4                        | 52 (2.1)                  |
| TX                        | 133 (4.6)                 |
| Tis                       | 24 (1.0)                  |
| 2018 FIGO stage           |                           |
| I                         | 1259 (51.6)               |
| II                        | 383 (15.7)                |
| III                       | 502 (20.6)                |
| IV                        | 188 (7.7)                 |
| Unknown/Tis               | 109 (4.5)                 |
| 2014 FIGO stage           |                           |
| I                         | 1395 (57.2)               |
| II                        | 615 (25.2)                |
| III                       | 133 (5.5)                 |
| IV                        | 181 (7.4)                 |
| Unknown/Tis               | 117 (4.8)                 |
chemoradiotherapy. While various criteria are used to select the appropriate treatment, radical hysterectomy

Table 2. The histological distributions of stage IB1/IB2/IB3 based on the 2018 FIGO stage. FIGO International Federation of Gynecology and Obstetrics.

| Histological subtype          | 2018 FIGO IB1 | 2018 FIGO IB2 | 2018 FIGO IB3 |
|------------------------------|--------------|--------------|--------------|
| Squamous cell carcinoma      | n 147        | n 194        | n 97         |
| Adenocarcinoma               | n 53         | n 74         | n 24         |
| Adenosquamous carcinoma      | n 6          | n 8          | n 4          |
| Others                       | n 3          | n 7          | n 5          |

Figure 1. Kaplan–Meier analysis of survival for 2018 FIGO stages IB1/IB2/IB3.

Figure 2. Kaplan–Meier analysis of survival for 2018 FIGO stage III.
is generally performed for cases involving stage IIB or lower, while concurrent chemoradiotherapy is recommended for more advanced cases. Some patients with early-stage disease have had their lymph node status diagnosed based on imaging, which may help guide the use of adjuvant treatment when metastasis is confirmed via lymphadenectomy and during surgery. Within the same disease stage, lymph node metastasis appears to be associated with a poor prognosis, although this does not appear to outweigh the prognostic relevance of the primary cervical mass status. For example, based on the 2018 FIGO system, surgical treatment might be selected for patients with lymph node metastasis that is identified via imaging (i.e., stage IIIC), regardless of the primary tumor's status, while other patients might receive concurrent chemoradiotherapy based on the tumor's size and adjacent organ invasion, even if they were also diagnosed with stage IIIC disease. This may cause issues in the real-world management of these patients.

In conclusion, this retrospective study surveyed data from the Korean national cancer registry and classified the cases according to the 2014 and 2018 FIGO systems. The effectiveness of the stage IB subdivisions in the 2018 FIGO system was not confirmed, which may have been related to the relatively small sample size. Furthermore, stage IIIC disease had a better prognosis than stage IIIA/IIIB disease based on the 2018 FIGO staging system, and there was substantial heterogeneity among stage IIIC cases. Additional discussion is needed to address how lymph node status should be managed in the FIGO staging system for Korean patients with cervical cancer.

Methods
Study population and methods. This study evaluated data from patients who were registered in the Korean Central Cancer Registry, which is a nationwide cancer registry that includes > 95% of Korean cancer cases. For the present study, a random sample was selected from the Korean Central Cancer Registry to obtain additional data regarding 10% of patients diagnosed with cervical cancer between 2010 and 2015. The study's retrospective protocol was reviewed and approved by the institutional review board of the National Cancer Center (approval number: NCC2019-0060), and the requirement for informed consent was waived. All study methods complied with the applicable national guidelines and regulations regarding the use of registry data.

A standardized protocol was used for a collaborative stage data collection system, which was developed by the American Joint Committee on Cancer to collect basic information required for cancer staging. This system was used to collect data regarding prognostic factors required for stage grouping (tumor size, lymph node status, and metastasis at diagnosis) and additional recommended factors (pelvic nodal status, para-aortic nodal status, mediastinal nodal status, and scalene nodal status).

The sampled survey database uses variables that are similar to those used by the Surveillance, Epidemiology, and End Results database rather than being based on the FIGO system. After the data were sorted according to the TNM criteria, the cases were classified according to the 2014 and 2018 FIGO staging systems. Patients were followed until December 31, 2017, and survival outcomes were compared between the various stages that were determined using the 2014 and 2018 FIGO staging systems.

Statistical analysis. Clinical characteristics were grouped as categorical variables and data were reported as number and percentage. The Kaplan–Meier method was used to create overall survival curves for the various stage groups, and the curves were compared using the log-rank test. Differences were considered statistically significant at P values < 0.05. All analyses were performed using SAS software (version 9.4; SAS Institute Inc., Cary, NC, USA).

Figure 3. Distribution of 2014 FIGO stages in the 2018 FIGO stages IIIC1 (a) and IIIC2 (b).
Data availability
All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).

Received: 23 September 2020; Accepted: 10 March 2021
Published online: 26 March 2021

References
1. Koh, W. J. et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 17, 64–84 (2019).
2. Koh, W. J. et al. Uterine Neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 16, 170–199 (2018).
3. Morgan, R. J. Jr. et al. Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 14, 1134–1163 (2016).
4. Pecorelli, S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 105, 103–104 (2009).
5. Pecorelli, S., Zigliani, L. & Odicino, F. Revised FIGO staging for carcinoma of the cervix. Int. J. Gynaecol. Obstet. 105, 107–108 (2009).
6. Figo Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int. J. Gynaecol. Obstet. 125, 97–98 (2014).
7. Bhata, N., Aoki, D., Sharma, D. N. & Sankaranarayanan, R. Cancer of the cervix uteri. Int. J. Gynaecol. Obstet. 143(Suppl 2), 22–36 (2018).
8. Cohen, P. A., Jhingran, A., Oaknin, A. & Denny, L. Cervical cancer. Lancet 393, 169–182 (2019).
9. Del Carmen, M. G. et al. Isolated para-aortic lymph node metastasis in FIGO stage IIA–IB2 carcinoma of the cervix: Revisiting the role of surgical assessment. Gynecol. Oncol. 150, 406–411 (2018).
10. Negrao, M. V., Lima, J. M., Silva, S. C., Diz, M. D. & da Costa Miranda, V. Management of para-aortic lymph node disease in patients with cervical cancer: What is the best approach?. Int. J. Gynecol. Cancer 27, 543–549 (2017).
11. Ramirez, P. T. et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N. Engl. J. Med. 379, 1895–1904 (2018).
12. Cibula, D. et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Virchows Arch. 472, 919–936 (2018).
13. Matsuo, K., Machida, H., Mandelbaum, R. S., Konishi, I. & Mikami, M. Validation of the 2018 FIGO cervical cancer staging system. Gynecol. Oncol. 152, 87–93 (2019).
14. Somashekhar, S. P. & Ashwin, K. R. Management of early stage cervical cancer. Rev. Recent Clin. Trials 10, 302–308 (2015).
15. Kim, S. I. et al. Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer. Gynecol. Oncol. 153, 3–12 (2019).
16. Leiata, M. M. Jr. The LACC Trial: Has minimally invasive surgery for early-stage cervical cancer been dealt a knockout punch?. Int. J. Gynecol. Cancer 28, 1248–1250 (2018).
17. Cibula, D. et al. New classification system of radical hysterectomy: Emphasis on a three-dimensional anatomic template for para-aortic resection. Gynecol. Oncol. 122, 264–268 (2011).
18. Querleu, D. & Morrow, C. P. Classification of radical hysterectomy. Lancet Oncol. 9, 297–303 (2008).
19. Drescher, C. W., Hopkins, M. P. & Roberts, J. A. Comparison of the pattern of metastatic spread of squamous cell cancer and adenocarcinoma of the uterine cervix. Gynecol. Oncol. 33, 340–343 (1989).
20. Green, J. et al. Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20–44 years: The UK National Case-Control Study of Cervical Cancer. Br. J. Cancer 89, 2078–2086 (2003).
21. Gien, L. T., Beauchemin, M. C. & Thomas, G. Adenocarcinoma: A unique cervical cancer. Gynecol. Oncol. 116, 140–146 (2010).
22. Pan, X. et al. Does adenocarcinoma have a worse prognosis than squamous cell carcinoma in patients with cervical cancer? A real-world study with a propensity score matching analysis. J. Gynecol. Oncol. 31, e80 (2020).
23. Bhata, N., Berek, J., Cuello Fredes, M., Denny, L. & Grenman, S. Corrigendum to revised FIGO staging for carcinoma of the cervix uteri. Int. J. Gynaecol. Obstet. 145, 129–135 (2019).
24. Cibula, D. et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother. Oncol. 127, 404–416 (2018).
25. Collaborative Stage Data Collection System Version 02.02 [Internet]. American Joint Committee on Cancer; c2010. http://cancerstaging.org/ctstage/software/index.html.

Author contributions
Y.J.W.: project development, data acquisition, manuscript writing. W.S.: conception and design, manuscript writing. T.Y.H.: data collection. Y.R.P.: data analysis. M.C.L.: data interpretation. All authors: critical revision and final approval of the manuscript.

Funding
This study was supported by a research grant from the National Cancer Center, Republic of Korea [1910132].

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-86283-2.

Correspondence and requests for materials should be addressed to Y.-J.W.

Reprints and permissions information is available at www.nature.com/reprints.
Publisher's note  Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021